Search

Displaying results 1451 - 1460 of 4588 in total
  1. Drug

    Ivacaftor

    go.drugbank.com/drugs/DB08820
    ApprovedInvestigational

    It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012[L768], and by Health Canada in late 2012. … [L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein

  2. Drug

    Amitriptyline

    go.drugbank.com/drugs/DB00321
    ApprovedInvestigational

    ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961.

  3. Drug

    Balsalazide

    go.drugbank.com/drugs/DB01014
    Approved

    Balsalazide works by deliverying mesalazine to the large intestine to act directly on ulcerative colitis. Mesalazine is also known as 5-aminosalicylic acid, or 5-ASA.

  4. Drug

    Pentagastrin

    go.drugbank.com/drugs/DB00183
    Approved

    It works by stimulating the secretion of gastric acid, pepsin, and intrinsic factor. It has also been used as a diagnostic aid.

  5. Drug

    Teduglutide

    go.drugbank.com/drugs/DB08900
    ApprovedInvestigational

    Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). … It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology.

  6. Drug

    Lumateperone

    go.drugbank.com/drugs/DB06077
    ApprovedInvestigational

    [A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity. … [L10902] Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological

  7. Drug

    Ozanimod

    go.drugbank.com/drugs/DB12612
    ApprovedInvestigational

    It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020. … [L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020.

  8. Drug

    Nivolumab

    go.drugbank.com/drugs/DB09035
    ApprovedInvestigational

    [A35203] It was developed by Bristol Myers Squibb.[L12129] Nivolumab was granted FDA approval on 22 December 2014.

  9. Drug

    Adecatumumab

    go.drugbank.com/drugs/DB05006
    Investigational

    EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer.

  10. Drug

    Gallium nitrate

    go.drugbank.com/drugs/DB05260
    ApprovedInvestigational

    Gallium nitrate is a nitrate salt of DB14524, a heavy metal that has been used as a diagnostic agent. Gallium nitrate is reported to possess antiresorptive and hypocalcemic effects on bone. GANITE, a product of gallium nitrate previously...